Pharmstandard to Buy Ingredient Supplier for $590 Million

Published: Aug 13, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Russian drugmaker Pharmstandard has agreed to buy a supplier of ingredients for its flagship anti-viral and anxiety drugs for $590 million, as part of a plan to spin off its over-the-counter (OTC) business. The plan to purchase Bever Pharmaceutical prompted a sell-off in Pharmstandard's shares when it was first announced in July. Analysts were concerned about a lack of information regarding Bever or a clear reason for the deal.

Help employers find you! Check out all the jobs and post your resume.

Back to news